Damora Therapeutics, Inc.
No SEC Form 4 filings for $DMRA in the last 30 days.
See all $DMRA insider activity →Damora Therapeutics (DMRA), a biotech firm, granted equity awards to three new employees. The awards include options for 135,400 shares, vesting over four years, with an exercise price of $28.18 per share. DMRA's stock closed at $28.18, up 0.14%.
Damora Therapeutics, Inc. (DMRA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-3.1 3 dmra-ex3_1.htm EX-3.1 EX-3.1 Exhibit 3.1 THE COMPANIES ACT (AS AMENDED) COMPANY LIMITED BY SHARES Memorandum OF association of Damora Therapeutics, Inc. (ADOPTED BY SPECIAL RESOLUTION PASSED ON 9 FEBRUARY 2026 AND EFFECTIVE AS OF 16 JULY 2026) THE COMPANIES ACT (AS AMEND
Damora Therapeutics (NASDAQ: DMRA) said it completed its redomestication from Delaware to the Cayman Islands effective July 16, 2026. Each Delaware common share converted into one ordinary share, and preferred shares into corresponding preferred shares. From July 20, 2026, ordinary shares trade on Nasdaq under a new CUSIP while the ticker remains DMRA; the company said business and obligations are unchanged.
Over the past 7 days, alphai's AI scored 1 news story mentioning DMRA (Damora Therapeutics, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Small dilution from option grants; limited immediate price impact.
The filing confirms a material definitive agreement exists, but the excerpt does not disclose deal terms, counterparties, or financial impact.
Corporate domicile change with a new CUSIP, but no stated change to business, management, assets, or liabilities.
Routine shareholder-meeting outcomes; limited direct fundamental signal beyond governance/board continuity.
alphai scores every news story that mentions DMRA with an AI model for sentiment and relevance, and aggregates insider trades from Damora Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Damora Therapeutics (DMRA), a biotech firm, granted equity awards to three new employees. The awards include options for 135,400 shares, vesting over four years, with an exercise price of $28.18 per share. DMRA's stock closed at $28.18, up 0.14%.
1 min readDamora Therapeutics, Inc. (DMRA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-3.1 3 dmra-ex3_1.htm EX-3.1 EX-3.1 Exhibit 3.1 THE COMPANIES ACT (AS AMENDED) COMPANY LIMITED BY SHARES Memorandum OF association of Damora Therapeutics, Inc. (ADOPTED BY SPECIAL RESOLUTION PASSED ON 9 FEBRUARY 2026 AND EFFECTIVE AS OF 16 JULY 2026) THE COMPANIES ACT (AS AMEND
2 min readDamora Therapeutics (NASDAQ: DMRA) said it completed its redomestication from Delaware to the Cayman Islands effective July 16, 2026. Each Delaware common share converted into one ordinary share, and preferred shares into corresponding preferred shares. From July 20, 2026, ordinary shares trade on Nasdaq under a new CUSIP while the ticker remains DMRA; the company said business and obligations are unchanged.
2 min readDamora Therapeutics, Inc. (DMRA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001800315 0001800315 2026-04-28 2026-04-28 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17 ,
2 min read
